Forecast
| Buy |
2 |
| Hold |
0 |
| Sell |
0 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
In the last year, Better Therapeutics Aktie had revenue of €0 and net profit of -€37.07M
| (EUR) | 2022 | YoY |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | -2.54M | 78.69% |
| Net profit | -37.07M | 4.50% |
| EBITDA | -33.13M | 2.62% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €4.97K |
Number of shares | 54.52M |
52-week high/low | €0.000182 - €0.0000911 |
| Dividends | No |
Beta | 0.18 |
P/E ratio | 0.00 |
PEG ratio | 0.00 |
P/B ratio | 0.00 |
P/S ratio | 0.00 |
Company profile
Better Therapeutics, Inc. engages in developing software-based prescription digital therapeutics (PDT) platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States. Its lead product candidate in development is BT-001, an investigational PDT platform that uses digitally delivered Nutritional Cognitive Behavioral Therapy to treat type 2 diabetes. The company's products under development also include BT-002, a PDT that help patients with hypertension improve their blood pressure; and BT-003, a PDT that help patients with hyperlipidemia enhance cholesterol levels. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.
| Name | Better Therapeutics Aktie |
| CEO | Craig R. Jalbert |
| Headquarters | San Francisco,
ca USA |
| Website | |
| Sector | Health Care |
| Industry | Health Care Providers & Services |
| IPO | 03/17/2021 |
| Employees | 54 |
Deep Dive
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | BTTX |